These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16848689)

  • 21. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
    Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
    J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment.
    Tarazi FI; Florijn WJ; Creese I
    Neuroscience; 1997 Jun; 78(4):985-96. PubMed ID: 9174067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.
    Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Barton HA; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
    Pharm Res; 2016 Apr; 33(4):1003-17. PubMed ID: 26718955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.
    Gurevich EV; Bordelon Y; Shapiro RM; Arnold SE; Gur RE; Joyce JN
    Arch Gen Psychiatry; 1997 Mar; 54(3):225-32. PubMed ID: 9075463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic-evoked dopamine supersensitivity.
    Servonnet A; Samaha AN
    Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine receptor heteromers: biasing antipsychotics.
    Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F
    Future Med Chem; 2018 Dec; 10(23):2675-2677. PubMed ID: 30518245
    [No Abstract]   [Full Text] [Related]  

  • 31. Extrastriatal dopamine D
    Nørbak-Emig H; Pinborg LH; Raghava JM; Svarer C; Baaré WFC; Allerup P; Friberg L; Rostrup E; Glenthøj B; Ebdrup BH
    World J Biol Psychiatry; 2017 Oct; 18(7):539-549. PubMed ID: 27782768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D4 receptors and development of newer antipsychotic drugs.
    Kulkarni SK; Ninan I
    Fundam Clin Pharmacol; 2000; 14(6):529-39. PubMed ID: 11206702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of dopamine D
    Egusquiza I; Munarriz-Cuezva E; Segarra R; González-Maeso J; Callado LF; Meana JJ; Diez-Alarcia R
    Pharmacol Rep; 2021 Aug; 73(4):1136-1146. PubMed ID: 34196951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new framework for investigating antipsychotic action in humans: lessons from PET imaging.
    Kapur S
    Mol Psychiatry; 1998 Mar; 3(2):135-40. PubMed ID: 9577837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.